Master formulation and compounding records

Records are kept only in this browser; nothing is sent to ClinDose. Export a file to move them. Sign in to also save to your account.

Ingredients

Ingredient chips: FDA 503A categories and lists, 21 CFR 216.24, and NIOSH hazardous drugs. Check an ingredient in detail, including FDA shortages.

Equipment
Compounding steps
Quality control

Beyond-use date

Current: 14 days · No cited stability study for this storage condition: USP <795> default BUD only.

Work out the BUD
Preparation
Dosage form
Storage

Beyond-use date

14 days

Refrigerator

  • Nonpreserved aqueous dosage form: 14 days, refrigerated.

USP <795> §10.4 (CNSPs requiring shorter BUDs), Table 4 (BUD limits by type of preparation)

Rules current as of the USP <795> and <797> revisions official November 1, 2023. Verify against the current official USP chapter before assigning a BUD.

References

Master formulation record: Rimantadine oral suspension 10 mg/mL

Oral suspension · Oral · Nonsterile (USP <795>) · Batch 100 mL

Ingredients

IngredientRoleQuantity
Rimantadineactive
Ora-Sweetvehicle mL

Equipment

  • Class A prescription balance or electronic balance
  • Mortar and pestle
  • Graduated cylinder

Compounding steps

  1. Follow the label's preparation instructions (quoted in the reference).

Quality control

  • Visual inspection: uniform appearance, no foreign matter
  • Final volume or weight checked

Packaging, storage, and BUD

Container: PET plastic bottle · Storage: Refrigerator · BUD: 14 days

Basis: No cited stability study for this storage condition: USP <795> default BUD only. USP <795> §10.4 (CNSPs requiring shorter BUDs), Table 4 (BUD limits by type of preparation)

Labeling

Shake well. Store as directed. Discard after the beyond-use date.

References

  1. FDA label (Rimantadine Hydrochloride), Dosage and Administration: Compounding of an Oral Suspension from Rimantadine Hydrochloride Tablets to prepare an oral suspension for administration to children and patients with difficulty swallowing tablets. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f7d69a-820b-4c75-a31d-b2104c019c12
Prepared by
Approved by
Date

Record contents follow the master formulation and compounding record sections of USP <795> and <797>; check your state board's requirements. For licensed clinicians. Use with clinical judgment.